Rheumatology Medical News about Osteoporosis Risedronate Ibandronate

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
HHS Weighs In On Health Reform

Dorothy J. Schirf, MD

Technology Advances

Over-the-Counter Nanotech Test for Prostate Cancer Anticipated

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/22/09

Epstein S et al. – Risedronate 150mg once monthly has demonstrated less reduction of BTM and non–inferior BMD gains versus daily, whereas 150mg once monthly ibandronate has demonstrated BTM suppression within the premenopausal range and BMD gains superior to the daily regimen. Furthermore, ibandronate has demonstrated antifracture efficacy with intermittent dosing in two pooled analyses. Risedronate has yet to demonstrate anti–fracture efficacy with an extended (intermittent) dosing regimen.

<< Previous
S-Adenosylmethionine for osteoarthritis of the knee or hip

Next >>
The effect of religious practice on the prevalence of knee...